rupert vessey  juno therapeutics inc  zoominfocom juno therapeutics appoints rupert vessey to board of directors  business wire juno therapeutics appoints rupert vessey to board of directors april    am eastern daylight time seattlebusiness wirejuno therapeutics inc nasdaq juno a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer today announced it has appointed to its board of directors dr rupert vessey president of research and early development of celgene corporation dr vessey brings significant drug development capabilities to the juno board before joining celgene in january  dr vessey was senior vice president of early development and discovery sciences at merck and had numerous roles of increasing responsibility at glaxosmithkline in drug discovery experimental medicine and early clinical development of therapeutics for respiratory and immune diseases “rupert has tremendous knowledge in immunology and experience in both drug development and building an efficient world class research organization that will be invaluable during this phase of growth at juno” said hans bishop juno’s president and ceo “our collaboration with celgene is an important component of our business and we are pleased to have rupert’s extensive skills added to our board” “i believe engineered cell therapy will play an increasingly important role in our industry’s future and i am excited to join juno’s board of directors” said dr vessey “celgene and juno intend to lead this field and bring these potentially transformative therapies to patients around the world i look forward to working with management and the rest of the board to advance the pipeline and achieve these goals” dr vessey will serve as celgene’s designated appointee to the juno board tom daniel md joined the juno board of directors in  upon the closing of the celgene  juno collaboration agreement as the celgene designated appointee dr daniel has agreed to remain on the board as an independent director dr vessey graduated from oxford university with degrees in physiological sciences ma clinical medicine bm bch and molecular immunology dphil he is an elected fellow of the royal college of physicians about juno juno therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine juno is developing cellbased cancer immunotherapies based on chimeric antigen receptor and highaffinity t cell receptor technologies to genetically engineer t cells to recognize and kill cancer juno is developing multiple cellbased product candidates to treat a variety of bcell malignancies as well as solid tumors several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date junos longterm aim is to leverage its cellbased platform to develop new product candidates that address a broader range of cancers and human diseases juno brings together innovative technologies from some of the worlds leading research institutions including the fred hutchinson cancer research center memorial sloan kettering cancer center seattle childrens research institute scri the university of california san francisco and the national cancer institute juno therapeutics has an exclusive license to the st jude children’s research hospital patented technology for cddirected product candidates that use bb which was developed by dario campana chihaya imai and st jude children’s research hospital juno’s product candidate jcar was developed in collaboration with scri and others about the junocelgene collaboration celgene corporation and juno therapeutics formed a collaboration in june  under which the two companies will leverage t cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on chimeric antigen receptor car and t cell receptor tcr technologies in april  celgene exercised its option to develop and commercialize the juno cd program outside north america and china forwardlooking statements this press release contains “forwardlooking statements” within the meaning of the private securities litigation reform act of  section a of the securities act of  and section e of the securities exchange act of  including statements regarding juno’s mission progress and business plans and the potential of the collaboration between juno and celgene forwardlooking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forwardlooking statements and reported results should not be considered as an indication of future performance these risks and uncertainties include but are not limited to risks associated with the success cost and timing of junos product development activities and clinical trials junos ability to obtain regulatory approval for and to commercialize its product candidates junos ability to establish a commerciallyviable manufacturing process and manufacturing infrastructure regulatory requirements and regulatory developments success of junos competitors with respect to competing treatments and technologies junos dependence on thirdparty collaborators and other contractors in junos research and development activities including for the conduct of clinical trials and the manufacture of junos product candidates junos dependence on celgene for the development and commercialization outside of north america and china of juno’s cd product candidates and any other product candidates for which celgene exercises an option juno’s dependence on jw therapeutics shanghai co ltd over which juno does not exercise complete control for the development and commercialization of product candidates in china junos ability to obtain maintain or protect intellectual property rights related to its product candidates amongst others for a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forwardlooking statements as well as risks relating to junos business in general see junos annual report on form k filed with the securities and exchange commission on march   and juno’s other periodic reports filed with the securities and exchange commission these forwardlooking statements speak only as of the date hereof juno disclaims any obligation to update these forwardlooking statements contacts juno therapeutics incinvestor relationsnicole keith nikkikeithjunotherapeuticscomormediachristopher williams chriswilliamsjunotherapeuticscom contacts juno therapeutics incinvestor relationsnicole keith nikkikeithjunotherapeuticscomormediachristopher williams chriswilliamsjunotherapeuticscom search advanced news search advanced news search log in sign up rupert vessey celgene corp profile  biography  bloomberg feedback rupert vessey exec vppresresearch  early dev celgene corp career history exec vppresresearch  early dev celgene corp present senior vptranslational development celgene corp  website wwwcelgenecom corporate information address  morris avenue summit nj  united states phone  fax  web url wwwcelgenecom from the web personal information education university of oxford graduated university of oxford phd memberships board memberships juno therapeutics inc board member present other memberships royal college of physicians fellow sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data rupert vessey celgene corporation president research  early development  evp  redbooks brands marketers agencies search less sell more    sign in get a free trial    contact us   rupert vessey president research  early development  evp celgene corporation email realtime sales trigger feed  generated by redbooks machine learning and natural language processing technology tracking  news sources to aggregate all new executives jobrole changes and news on decision makers brands and agencies in the mediamarketing industry this sales feed is for rupert vessey at celgene corporation rupert vessey works as president research  early development  evp  acting in a executive management role  celgene corporation is a leader in pharmaceuticals  health care products  redbooks tracks personnel changes for advertisers spending over  million annually for more executive management leads or mediamarketing prospecting automation start a free trial now recent related news  celgene celg q  results  earnings call transcript scott andrew smith  celgene corp rupert vessey  celgene corp christopher raymond  raymond james  associates inc  people in this article mark alles  patrick e flanigan iii  peter n kellogg  robert j hugin  rupert vessey  scott a smith  terrie curran  celgene corporation celg receiving somewhat favorable press coverage analysis finds  the transaction was disclosed in a filing with the securities  exchange commission which can be accessed through this link also insider rupert vessey sold  shares of the company’s stock in a transaction that occurred on thursday june th the shares were sold at an average price of  for a total transaction of   people in this article rupert vessey learn more about rupert vessey and  key contacts   create targeted lead lists   gain insider knowledge with advanced machine  learning   realtime verified contact info enter work email please enter email address please enter valid email address learn more about rupert vessey and  key contacts first name  please enter first name last name  please enter last name company name  please enter company name email  phone  please enter phone number please enter  digits number what industry are you in    please select one the categories below please enter value for the industry  media sales  production  adtechmartech  sponsorship sales   agency new business   other what is your role    please select one the categories below please enter value for the role   csuite   vpmanager   sales rep   other thank you for registering for a free redbookscom trial we are processing your request and will be in touch shortly to get you started for immediate assistance please call us at   or email us at inforedbookscom home learn more free trial features ad think events thought leadership events top advertiser directory top agency directory add your agency update your agency agency showcase advertising associations creative spotlight services and suppliers about us blog contact us jobs terms  conditions privacy policy customer support   connect with us copyright   red books llc all rights reserved microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft whatsonthorold  news – analysis market news penny stock news stock news trending stock news todays date  saturday july th  welcome visitor     log in  market news more » south street advisors has trimmed its seagate technology stx stake  analysts covering weingarten realty investors wri darrin black south street advisors llc decreased seagate technology stx stake by  reported in q sec filing south street advisors llc sold  shares as seagate technology stx’s stock declined  the south street advisors llc holds  shares with  million value down from  last quarter seagate technology now has   zevin asset management lifted auto data processing adp stake weight watchers international wtw sentiment is  winifred garcia weight watchers international inc is a wellknown provider of weight management services the company has market cap of  billion the firm operates globally through a network of companyowned and franchise operations it has a  pe ratio the company’s branded services and products include meetings conducted by its franchisees digital weight  marshfield associates has lowered its cummins cmi position shorts at bunge limited bg lowered by  louis casey marshfield associates decreased cummins inc cmi stake by  reported in q sec filing marshfield associates sold  shares as cummins inc cmi’s stock rose  the marshfield associates holds  shares with m value down from  last quarter cummins inc now has b valuation the stock increased  or   ashford capital management cut meta financial group cash holding by  million suntrust banks cut its tractor supply co tsco position hm payson  company upped its phillips  psx position america first investment advisors has lifted its cdk global cdk position rothschild asset management has lifted lydall del ldl position by  million h lundbeck a s adr hluyy had  bulls lombard odier asset management switzerland sa has raised its ulta salon cosmetcs  frag i ulta holding prudential plc has trimmed its morgan stanley group ms holding hikari tsushin cut its medtronic mdt holding becton dickinson  company bdx shorts down by  teachers insurance  annuity association of america has cut rsp permian rspp position tricadia capital management lowered by  million its danaher del dhr stake capital research global investors cut its clubcorp holdings mycc stake nicholas investment partners lp has cut microsemi mscc holding whale rock capital management has cut by  million its epam sys epam stake physicians realty trust doc’s sentiment is  rbf capital has decreased pepsico pep holding by  tortoise energy infrastructure tyg has  sentiment rbf capital raised morgan stanley ms position by  million  bullish analysts covering perceptron inc prcp aviance capital management raised fluor flr position by  la quinta holdings lq had  bulls paloma partners management company has lifted celgene call celg position  analysts are bullish genesis energy lp gel last week partner fund management lp has increased salesforce com crm holding by  million  bullish analysts covering formfactor inc form raging capital management boosted ashford hospitality prime in ahp stake by  million banc california banc shorts up by  nokomis capital lifted intest intt holding by  shorts at blackrock blk raised by  viking global investors lp has lifted its biomarin pharmaceutical bmrn stake shorts at bank of america bac raised by  clearline capital lp has lowered its travelport worldwide ltd tvpt position alloy steel international aysi shorts down by  cushing asset management lp cut devon energy new dvn position acuity brands ayi si increased by  gates capital management has decreased by  million its davita dva position  analysts covering bancorpsouth inc bxs stock news more » nordic american tanker ltd nat reaches  after  up move state street decreased its chemtura chmt holding marguerite chambers the stock of nordic american tanker ltd nysenat is a huge mover today the stock increased  or  during  congress asset management company decreased its facebook fb position build a bear workshop bbw shorts down by  linda rogers congress asset management company decreased facebook inc fb stake by  reported in q sec filing congress asset management company  fj capital management has lowered its hometrust bancshares htbi holding investec asset management ltd has lifted by  million its thor industries tho holding adrian mccoy investec asset management ltd increased thor industries inc tho stake by  reported in q sec filing investec asset management  canyon capital advisors has cut its comcast new cmcsa holding select medical sem’s sentiment is  winifred garcia select medical holdings corporation is an operator of specialty hospitals outpatient rehabilitation clinics and occupational medicine centers in the united  nokomis capital decreased its echostar sats position city holding company chco had  bullish analysts ruchi gupta nokomis capital llc decreased echostar corp sats stake by  reported in q sec filing nokomis capital llc sold   valinor management has increased by  million its facebook fb holding zumiez zumz has  sentiment olga zumiez inc including its subsidiaries is a specialty retailer of apparel footwear accessories and hardgoods for young men and women  deere  company de reaches  high on jul  state street raised its hunt jb transprt svcs jbht stake winifred garcia the stock of deere  company nysede reached all time high today jul  and still has  target or  green square capital decreased by  its qualcomm qcom position bbt capital management has lowered st jude med stj holding by  million peter erickson bbt capital management llc decreased st jude med inc stj stake by  reported in q sec filing bbt capital  nokota management lp has raised intel intc position bio path holdings de bpth shorts increased by  whatsonthorold bio path holdings de nasdaqbpth had an increase of  in short interest bpth’s si was m shares in july  saba capital management lp raised by  million its tenet healthcare thc position tcw group has cut pfizer pfe holding by  million adrian erickson tcw group inc decreased pfizer inc pfe stake by  reported in q sec filing tcw group inc sold   northwestern mutual wealth management company has lifted its scana new scg position last week aixtron se etraixa analysts richard conner northwestern mutual wealth management company increased scana corp new scg stake by  reported in q sec filing northwestern mutual  valinor management has increased by  million its facebook fb holding zumiez zumz has  sentiment nwq investment management company increased symantec symc holding by  million  bullish analysts covering big  sporting goods bgfv alyeska investment group lp has boosted its tesaro tsro holding aytu bioscience inc common sto aytu shorts down by  mason street advisors boosted intercontinental exchange in ice holding axsome therapeutics axsm shorts up by  force capital management lowered its copart cprt stake edgewood management upped priceline grp pcln stake by  million white elm capital has lowered by  million its sei investments co seic stake sectoral asset management cut its celgene celg holding tcg bdc cgbd touches  high on jul   analysts covering ring energy nysemktrei point asia hong kong ltd has increased cognizant technology solutio ctsh stake by  shorts at average tech n v avgtf raised by  sequoia financial advisors has lifted its wal wmt holding ws management lllp has decreased united states stl new call x stake by  million weiss multistrategy advisers has increased its hain celestial group hain holding cg asset management has lowered its autodesk adsk stake free email newsletter enter your email address below to get the latest news and analysts ratings for your stocks with our free daily email newsletter top newsishares morningstar mid value idx etf jki trades at  after triangle vanguard ftse developed markets etf nysearcavea shorts up by  asset management lp trimmed dollar gen new dg position cyrusone cone sentiment is maltese capital management has cut southwest bancorp okla oksb holding analogic has  sentimentbrighton jones has cut its paccar pcar position mitchell capital management co decreased express scripts holdings co esrx position by group one trading lp decreased its macquarie infrastructure cor mic position last week servelec group plc lonserv analysts  copyright  whats on thorold inc  mmahotstuffcom       about  editorial  contact get the next big winner in your inbox before the bell listsconsumer eagle  dr rupert vessey  whitehouse station nj merck university of oxford  aboutmedr rupert vesseywhitehouse station njcurrently dr rupert vessey functions as head of early development and discovery sciences with merck research laboratories a research and development healthcare company dr vessey has been in the pharmaceutical industry since  having begun his tenure working for glaxosmithkline gsk in the united kingdom during his time at gsk he focused on drug discovery experimental medicine and early clinical development and contributed to projects involving dna vaccines and monoclonal antibodies over the course of his subsequent career with merck dr rupert vessey has served in roles such as vice president of drug discovery and site head for boston and kenilwortha fellow of the royal college of physicians in london dr rupert vessey completed his education and clinical training in the united kingdom he earned his md from oxford university and his phd from the institute for molecular medicine he also trained at the john radcliffe hospital and the national hospital for neurology and neurosurgery both in englandsportsrugbygardeningscientificpublicationsworkmerckeducationuniversity of oxfordjuno therapeutics appoints rupert vessey to board of directorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballjuno therapeutics appoints rupert vessey to board of directorsbusiness wireapril  reblogsharetweetshareseattlebusiness wirejuno therapeutics inc juno a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer today announced it has appointed to its board of directors dr rupert vessey president of research and early development of celgene corporationdr vessey brings significant drug development capabilities to the juno board before joining celgene in january  dr vessey was senior vice president of early development and discovery sciences at merck and had numerous roles of increasing responsibility at glaxosmithkline in drug discovery experimental medicine and early clinical development of therapeutics for respiratory and immune diseases“rupert has tremendous knowledge in immunology and experience in both drug development and building an efficient world class research organization that will be invaluable during this phase of growth at juno” said hans bishop juno’s president and ceo “our collaboration with celgene is an important component of our business and we are pleased to have rupert’s extensive skills added to our board”“i believe engineered cell therapy will play an increasingly important role in our industry’s future and i am excited to join juno’s board of directors” said dr vessey “celgene and juno intend to lead this field and bring these potentially transformative therapies to patients around the world i look forward to working with management and the rest of the board to advance the pipeline and achieve these goals”dr vessey will serve as celgene’s designated appointee to the juno board tom daniel md joined the juno board of directors in  upon the closing of the celgene  juno collaboration agreement as the celgene designated appointee dr daniel has agreed to remain on the board as an independent directordr vessey graduated from oxford university with degrees in physiological sciences ma clinical medicine bm bch and molecular immunology dphil he is an elected fellow of the royal college of physiciansabout junojuno therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine juno is developing cellbased cancer immunotherapies based on chimeric antigen receptor and highaffinity t cell receptor technologies to genetically engineer t cells to recognize and kill cancer juno is developing multiple cellbased product candidates to treat a variety of bcell malignancies as well as solid tumors several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date junos longterm aim is to leverage its cellbased platform to develop new product candidates that address a broader range of cancers and human diseases juno brings together innovative technologies from some of the worlds leading research institutions including the fred hutchinson cancer research center memorial sloan kettering cancer center seattle childrens research institute scri the university of california san francisco and the national cancer institute juno therapeutics has an exclusive license to the st jude children’s research hospital patented technology for cddirected product candidates that use bb which was developed by dario campana chihaya imai and st jude children’s research hospital juno’s product candidate jcar was developed in collaboration with scri and othersabout the junocelgene collaborationcelgene corporation and juno therapeutics formed a collaboration in june  under which the two companies will leverage t cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on chimeric antigen receptor car and t cell receptor tcr technologies in april  celgene exercised its option to develop and commercialize the juno cd program outside north america and chinaforwardlooking statementsthis press release contains “forwardlooking statements” within the meaning of the private securities litigation reform act of  section a of the securities act of  and section e of the securities exchange act of  including statements regarding juno’s mission progress and business plans and the potential of the collaboration between juno and celgene forwardlooking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forwardlooking statements and reported results should not be considered as an indication of future performance these risks and uncertainties include but are not limited to risks associated with the success cost and timing of junos product development activities and clinical trials junos ability to obtain regulatory approval for and to commercialize its product candidates junos ability to establish a commerciallyviable manufacturing process and manufacturing infrastructure regulatory requirements and regulatory developments success of junos competitors with respect to competing treatments and technologies junos dependence on thirdparty collaborators and other contractors in junos research and development activities including for the conduct of clinical trials and the manufacture of junos product candidates junos dependence on celgene for the development and commercialization outside of north america and china of juno’s cd product candidates and any other product candidates for which celgene exercises an option juno’s dependence on jw therapeutics shanghai co ltd over which juno does not exercise complete control for the development and commercialization of product candidates in china junos ability to obtain maintain or protect intellectual property rights related to its product candidates amongst others for a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forwardlooking statements as well as risks relating to junos business in general see junos annual report on form k filed with the securities and exchange commission on march   and juno’s other periodic reports filed with the securities and exchange commission these forwardlooking statements speak only as of the date hereof juno disclaims any obligation to update these forwardlooking statementsview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nextdynavax technologies corporation dvax meets the fda all eyes on heplisavsmarteranalystthis will be in everyones household by banyan hillsponsoredbehind uber’s messy ceo search is a divided boardroombloombergcelgene celg beats on q earnings  saleszacksthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsoredhere are the us targets north korea most likely wants to nukebusiness insiderapnewsbreak yellowstone park cracks down on sex harassmentassociated presschevron and exxon mobil have a tough path ahead nyse traderyahoo finance videodiscover it  out of  avg by k customersdiscover cardsponsoredstocks mixed after heavy earnings weektrump to cops please dont be too nice while arresting thugs and dont worry about their heads when you toss them in the paddy wagonbusiness insiderthe real reason overseas manufacturing is coming to americayahoo financeits easily the no  stock to ownbanyan hillsponsoredwells fargo faces angry questions after new sales abuses uncoveredreutersmy bullish view on stocks hasnt changed one iota nyse traderyahoo finance videotrump replaces chief of staff reince priebus with homeland security chief john kellydanielle this presidency is out of control muellerplease bring this travesty to a stop soonjoin the conversation  k rupert vessey  president research  early development at celgene corp news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink rupert vessey president research  early development at celgene corp overview in the news relationships paths education memberships career history boards  committees public holdings rupert vessey president research  early development at celgene corp overview age  born  board seats  number of relationships this person is connected to  people in the news see more pr newswire june   dragonfly therapeutics announces strategic collaboration with celgene to discover and develop novel natural killer nk cellbased immunotherapies using dragonflys trinkettm technology platform business wire may   juno therapeutics reports first quarter  financial results business wire april   juno therapeutics appoints rupert vessey to board of directors business wire january   celgene to acquire delinia inc business wire january   anokion announces exclusive strategic collaboration with celgene to develop novel toleranceinducing therapeutics for autoimmune diseases see full news coverage and complete stories with relsci professional create your news feed see more relationships see details jillian f evans cofounder at pharmakea inc john howard hutchinson cofounder at pharmakea inc kevin holme cofounder at pharmakea inc thomas daniel chairman at celgene research  development llc mervyn turner advisor at bay city capital llc michael rosenblatt cofounder at radius health inc richard klausner cofounder at juno therapeutics inc robert hariri cofounder at human longevity inc robert f williamson iii chief executive officer  director at pharmakea inc howard pien advisor life sciences at warburg pincus llc see  more listings with relsci professional start my free trial ➤ see  more paths to rupert vessey rupert vessey you connections via relationship science rupert vessey sync your contacts to see how you can connect with rupert vessey start my free trial ➤ see more educational background   university of oxford oxford is a collegiate university consisting of the central university and colleges the central university is composed of academic departments and research centres administrative departments libraries and museums the  colleges are selfgoverning and financially independent institutions which are related to the central university in a federal system there are also six permanent private halls which were founded by different christian denominations and which still retain their christian character dphil in molecular immunology  university of oxford  weatherall institute of molecular medicine medicine  oxford university medical school memberships member current royal college of physicians of london career history president research  early development   current celgene corp celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide at celgene we seek to deliver truly innovative and lifechanging drugs for our patients our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery the development and the commercialization of products for the treatment of cancer and other severe immune inflammatory conditions there are more than  clinical trials at major medical centers using compounds from celgene investigational compounds are being studied for patients with incurable hematological and solid tumor cancers including multiple myeloma myelodysplastic syndromes chronic lymphocyte leukemia cll nonhodgkins lymphoma nhl myelofibrosis small cell lung cancer and prostate cancer as committed as we are to clinical accomplishment we are equally committed to patient support which is a guiding principle at celgene we believe all who can benefit from our discoveries should have the opportunity to do so celgene puts patients first with industryleading programs that provide information support and access to our innovative therapies senior vice president of respiratory  immunology franchise current merck  co inc merck  co inc  dba merck sharp  dohme msd outside the united states and canada is an american pharmaceutical company and is one of the largest pharmaceutical companies in the world head early development  discovery sciences prior merck research laboratories merck research laboratories a subsidiary of merck  co inc is an american company located in boston ma that discovers develops and markets a broad range of human and animal health products senior director of discovery medicine prior glaxosmithkline plc ‘glaxosmithkline plc is a global healthcare company which engages in developing manufacturing and marketing of pharmaceutical products including vaccines over the counter medicines and healthrelated consumer products it operates through the following segments pharmaceuticals pharmaceuticals rd vaccines and consumer healthcare the pharmaceuticals business researches develops and makes available medicines that treat a variety of serious and chronic diseases the vaccines business produces pediatric and adult vaccines to prevent a range of infectious diseases including hepatitis a and b diphtheria tetanus and whooping cough measles mumps and rubella polio typhoid influenza and bacterial meningitis the consumer healthcare business markets a range of consumer health products based on scientific innovation the company was founded on december   and is headquartered in brentford united kingdom vice president prior target discovery inc target discovery inc provides scientific research services it discovers validates and utilizes protein isoforms to improve clinical diagnosis and the management of diseases the firm’s products address prostate cancer aggressiveness and chemotherapy selection in breast and ovarian cancer the company was founded by luke v schneider in  and is headquartered in palo alto ca boards  committees corporate boards ▾ member board of directors   current juno therapeutics inc juno therapeutics inc is a biopharmaceutical company which engages in the development of innovative cellular immunotherapy for the treatment of cancer it offers platforms which includes chimeric antigen receptors and tcell receptors the company was founded by hans e bishop lawrence corey richard d klausner stan riddell and robert t nelsen on august   and is headquartered in seattle wa director current pharmakea inc pharmakea inc develops small molecule drug candidates against protein targets involved in fibro proliferative diseases it discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases the company was founded by john howard hutchinson kevin holme and jilly evans in  and is headquartered in san diego ca nonprofit boards ▾ member immunology advisory council tenure unconfirmed harvard university  harvard medical school harvard medical school hms is the graduate medical school of harvard university it is located in the longwood medical area of the mission hill neighborhood of boston massachusettsthe school was founded by john warren on september   with benjamin waterhouse and aaron dexter public holdings restricted data only for relsci professional users start my free trial ➤ see more other affiliations rupert vessey is affiliated with celgene corp merck  co inc merck research laboratories glaxosmithkline plc target discovery inc juno therapeutics inc pharmakea inc harvard university  harvard medical school youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤